Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The revenues this quarter are in line with the outlook we envisaged for the year
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Subscribe To Our Newsletter & Stay Updated